1) http://www.ncbi.nlm.nih.gov/pubmed/15111379 - Arch Intern Med. 2004 Apr 26;164(8):910-3. "Only a small percentage of patients with ACE inhibitor-related angioedema continue with this symptom when switched to an ARB."
2) http://www.ncbi.nlm.nih.gov/pubmed/17225721 - Ann Allergy Asthma Immunol. 2007 Jan;98(1):57-63. " The mean time to onset of angioedema after initiation of therapy in 51 patients was 1.8 years. Also, none of the 6 patients, whose angioedema was attributed to an ACE-I who then received an ARB, developed recurrent angioedema in more than 8.1 patient-years of follow-up. "
3) http://www.ncbi.nlm.nih.gov/pubmed/19055203 - Ann Allergy Asthma Immunol. 2008 Nov;101(5):495-9. This is the meatanalysis I was referring to - " Any article that described a cohort of patients who had angioedema after taking an ACE-I, were subsequently exposed to an ARB, and were followed for a least 1 month were included. The risk of angioedema was 9.4% (95% confidence interval, 1.6%-17%) for possible cases and 3.5% (95% confidence interval, 0.0%-9.2%) for confirmed cases. CONCLUSIONS: Limited evidence suggests that for patients who develop angioedema when taking an ACE-I, the risk of development of any subsequent angioedema when taking an ARB is between 2% and 17%; for confirmed angioedema, the risk is 0% to 9.2%. This information will aid clinicians in counseling patients regarding therapy options after development of angioedema due to ACE-Is."
2) http://www.ncbi.nlm.nih.gov/pubmed/17225721 - Ann Allergy Asthma Immunol. 2007 Jan;98(1):57-63. " The mean time to onset of angioedema after initiation of therapy in 51 patients was 1.8 years. Also, none of the 6 patients, whose angioedema was attributed to an ACE-I who then received an ARB, developed recurrent angioedema in more than 8.1 patient-years of follow-up. "
3) http://www.ncbi.nlm.nih.gov/pubmed/19055203 - Ann Allergy Asthma Immunol. 2008 Nov;101(5):495-9. This is the meatanalysis I was referring to - " Any article that described a cohort of patients who had angioedema after taking an ACE-I, were subsequently exposed to an ARB, and were followed for a least 1 month were included. The risk of angioedema was 9.4% (95% confidence interval, 1.6%-17%) for possible cases and 3.5% (95% confidence interval, 0.0%-9.2%) for confirmed cases. CONCLUSIONS: Limited evidence suggests that for patients who develop angioedema when taking an ACE-I, the risk of development of any subsequent angioedema when taking an ARB is between 2% and 17%; for confirmed angioedema, the risk is 0% to 9.2%. This information will aid clinicians in counseling patients regarding therapy options after development of angioedema due to ACE-Is."
Please feel free to share or comment if you have some other ideas or data to share.
Thanks,
Arun Chawla, MD
Is there maybe a specific reaction to the ACE through the Bradykinin pathway that is lacking in the ARB? Is that the mechanism?
ReplyDelete